Zobrazeno 1 - 5
of 5
pro vyhledávání: '"A. I. Gosudarev"'
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 2, Pp 80-84 (2019)
The article discusses the development of a production technique for recombinant follicle-stimulating hormone used in the treatment of infertility, in the culture of Chinese hamster ovary cells. As part of the creation of the technological platform re
Externí odkaz:
https://doaj.org/article/1d44f86e9a6b4a849cf6927231a41100
Autor:
T. V. Budylskaya, D. V. Byrikhina, A. I. Gosudarev, V. D. Gusarova, F. M. Izhaeva, P. V. Mikhailov, D. A. Gusarov
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 1, Pp 74-85 (2019)
Biopharmaceuticals intended for gene therapy are mostly presented by supercoiled plasmid DNA obtained with bacteria cell lines. The properties of their formulations, including stability under different storage conditions, are barely studied. This art
Externí odkaz:
https://doaj.org/article/76a0936eb59442f9b13f8218878d28d5
Autor:
Ilias B. Esmagambetov, Ekaterina I. Ryabova, Artem A. Derkaev, Dmitry V. Shcheblyakov, Inna V. Dolzhikova, Irina A. Favorskaya, Daria M. Grousova, Mikhail A. Dovgiy, Vladimir V. Prokofiev, Andrey I. Gosudarev, Daria V. Byrikhina, Ilia D. Zorkov, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In cont
Externí odkaz:
https://doaj.org/article/435734489115452892c1fe539af6307b
Autor:
M. V. Serebryakova, B. S. Mel’nik, Yu. A. Khodak, A. I. Gosudarev, M. A. Polzikov, A. S. Semikhin, D. V. Byrikhina, M. S. Krasil’shchikova, I. I. Vorob’ev, O. V. Proskurina
Publikováno v:
Pharmaceutical Chemistry Journal. 50:753-760
Comparative analysis of the primary structure of recombinant human follicle-stimulating hormone (r-hFSH) in samples of follitropin alpha biosimilar (FAB) preparation and the reference drug Gonal-F showed they were identical while spectral analysis of
Autor:
D. A. Gusarov, A. F. Mironov, P. V. Mikhailov, F. M. Izhaeva, V. I. Shvets, T. A. Budyl’skaya, V. D. Gusarova, A. I. Gosudarev, D. V. Byrikhina
Publikováno v:
Pharmaceutical Chemistry Journal. 48:822-829
The development of domestic biogenerics to replace imported drugs is among the main goals of the Pharma-2020 strategy. Insulin glargine, a therapeutic polypeptide with sustained glycolytic activity, is one of the most important biogenerics. A systema